ArticleiScience2026
SHP2 regulates VEGFR2 Y1175/PLCγ signaling to impair tumor endothelial barrier stability.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor vasculature is abnormally formed, with an endothelial cell (EC) barrier lacking integrity, resulting in hyperpermeable vessels. Elevated VEGFA levels drive the formation of the dysfunctional vasculature by activating VEGFR2 signaling. The VEGFR2 tyrosine site pY1175 was recently shown to stimulate a PLCγ/eNOS/Src pathway, promoting vascular leakage and hindering therapeutic targeting and anti-tumor immunity. High endothelial PLCγ levels correlated to poor kidney cancer prognosis, which indicated endothelial PLCγ as a prognostic biomarker. In this study, we reveal SHP2 as a binding partner of pY1175 and show that SHP2 cooperates with PLCγ to mediate VEGFA-induced permeability in both healthy and tumor vasculatures. Targeting the VEGFR2/PLCγ/SHP2 axis-genetically or pharmacologically-reduces EC junctional phosphorylation to prevent VE-cadherin internalization, followed by reduced macromolecular leakage. Tumor EC expression of PLCγ or SHP2 is associated with vascular leakage in human kidney cancer, underscoring their potential as targets for vascular normalization and biomarkers for disease progression and treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.